GlobeNewswire: PolarityTE, Inc. Contains the last 10 of 209 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:17:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/08/09/1549705/0/en/PolarityTE-Inc-Announces-the-Addition-of-Ramses-Erdtmann-Managing-Partner-at-Point-Sur-Investors-and-Former-Executive-at-Pharmacyclics-and-David-Seaburg-Managing-Director-at-Cowen-.html?f=22&fvtc=4&fvtv=37419PolarityTE, Inc. Announces the Addition of Ramses Erdtmann, Managing Partner at Point Sur Investors and Former Executive at Pharmacyclics, and David Seaburg, Managing Director at Cowen and CNBC Contributor, to the Board of Directors2018-08-09T12:30:00Z<![CDATA[SALT LAKE CITY, Aug. 09, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced the addition of Ramses (Rainer) Erdtmann and David Seaburg to the Board of Directors. Mr. Erdtmann is a Managing Partner at Point Sur Investors, a biotech investment fund focused on innovative therapies. Mr. Erdtmann previously worked at Pharmacyclics from 2008 through 2015 and remained with AbbVie as a consultant until 2016 post the acquisition of Pharmacyclics by AbbVie. Mr. Seaburg is a Managing Director at Cowen, Inc. and a CNBC contributor, regularly commenting on the financial prospects of companies and interacting with management teams and institutional investors.]]>https://www.globenewswire.com/news-release/2018/07/31/1544574/0/en/PolarityTE-Inc-Announces-Alain-Adam-as-Vice-President-of-Sales.html?f=22&fvtc=4&fvtv=37419PolarityTE, Inc. Announces Alain Adam as Vice President of Sales2018-07-31T12:00:00Z<![CDATA[SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL) today announced the appointment of Alain Adam as Vice President of Sales. Mr. Adam will lead the company’s continued development of its commercial strategy, sales force buildout, and execution.]]>https://www.globenewswire.com/news-release/2018/07/25/1541947/0/en/PolarityTE-Inc-Provides-Commercial-Update.html?f=22&fvtc=4&fvtv=37419PolarityTE, Inc. Provides Commercial Update2018-07-25T13:00:00Z<![CDATA[SALT LAKE CITY, July 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company, today announced an update on the Company’s commercial progress. The Company’s first product, SkinTE, has transitioned into Stage 2 of commercialization and has continued to be successful in regenerating autologous full-thickness skin in the treatment of complex wounds including acute and chronic wounds, traumatic and surgical defects, burn wound reconstruction and skin graft replacement. With continued growing physician, facility, and VAC committee purchase agreement approvals, the Company has begun generating revenues while improving the lives of patients.]]>https://www.globenewswire.com/news-release/2018/07/02/1532355/0/en/PolarityTE-Adds-Peter-Cohen-Former-Board-Member-of-the-NYSE-and-Chairman-and-CEO-of-Cowen-Inc-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=37419PolarityTE Adds Peter Cohen, Former Board Member of the NYSE and Chairman and CEO of Cowen Inc., to the Board of Directors2018-07-02T12:00:00Z<![CDATA[SALT LAKE CITY, July 02, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that Peter Cohen will join PolarityTE’s Board of Directors. Mr. Cohen is well known within the investment community having previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman Cowen, and Republic New York Securities. Mr. Cohen is currently a Trustee of Mount Sinai Medical Center and has served on its board for approximately thirty years. With the addition of Mr. Cohen, PolarityTE will increase the independence of its Board of Directors, with five of the Board’s seven Directors being independent.]]>https://www.globenewswire.com/news-release/2018/06/27/1530272/0/en/PolarityTE-Provides-Update-on-Key-Opinion-Leader-Event-and-Addresses-Misleading-Report.html?f=22&fvtc=4&fvtv=37419PolarityTE Provides Update on Key Opinion Leader Event and Addresses Misleading Report2018-06-27T12:00:00Z<![CDATA[SALT LAKE CITY, June 27, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that the Company hosted a successful meeting of key opinion leaders in New York City on June 25, 2018, addressing the use of SkinTE™ in complex wounds requiring cutaneous reconstruction. The three medical providers who presented at the event discussed the standard of care, limitations in the field, and their use of SkinTE, including patient outcomes and ongoing cases. The presentations emphasized the challenging nature of many of the complex wounds treated, and the encouraging and positive healing observed to date.]]>https://www.globenewswire.com/news-release/2018/06/25/1528830/0/en/PolarityTE-Added-to-Russell-3000-and-Russell-2000-Indexes.html?f=22&fvtc=4&fvtv=37419PolarityTE Added to Russell 3000® and Russell 2000® Indexes2018-06-25T11:30:00Z<![CDATA[SALT LAKE CITY, June 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that it is set to join the Russell 3000® and Russell 2000® Indexes at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to the final list of additions posted on June 22, 2018.]]>https://www.globenewswire.com/news-release/2018/06/21/1527851/0/en/UPDATE-PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=37419UPDATE - PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial Officer2018-06-21T12:32:29Z<![CDATA[Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS]]>https://www.globenewswire.com/news-release/2018/06/21/1527796/0/en/PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=37419PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial Officer2018-06-21T12:00:00Z<![CDATA[Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS]]>https://www.globenewswire.com/news-release/2018/06/18/1525740/0/en/PolarityTE-Provides-Corporate-Update-on-Company-Progress.html?f=22&fvtc=4&fvtv=37419PolarityTE Provides Corporate Update on Company Progress2018-06-18T12:00:00Z<![CDATA[SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced an update on the Company’s progress. Over the last several months PolarityTE has achieved multiple milestones and continues to execute on its strategy to commercialize SkinTE and position the Company for growth. Some recent items to note include:]]>https://www.globenewswire.com/news-release/2018/06/05/1516997/0/en/PolarityTE-Announces-Pricing-of-Public-Follow-on-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=37419PolarityTE Announces Pricing of Public Follow-on Offering of Common Stock2018-06-05T12:49:02Z<![CDATA[SALT LAKE CITY, June 05, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that the pricing of an underwritten public follow-on offering of approximately $55 million of shares of its common stock. PolarityTE has granted the underwriters for the offering a 30-day option to purchase up to approximately $8.2 million of additional shares of its common stock at the same price. The offering is expected to close on or about June 7, 2018, subject to satisfaction of customary closing conditions.]]>